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Background: Implanted defibrillators are capable of recording activity data based on 
company-specific proprietary algorithms. This study aimed to determine the prognostic 
significance of baseline and decline in device-derived activity level across different device 
companies in the real world.  
Methods: We performed a retrospective cohort study of patients (n=280) who underwent a 
defibrillator implantation (Boston, Medtronic, St. Jude and Biotronik) for primary prevention 
at the University of Michigan from 2014 to 2016. Graphical data obtained from device 
interrogations were retrospectively converted to numerical data. The activity level averaged 
over a month from a week post-implantation was used as baseline.  Subsequent weekly 
average activity levels (SAL) were standardized to this baseline. SAL below 59.4% was used 
as a threshold to group patients. All-cause mortality and death/heart failure were the primary 
end-points of this study.  
Results: Fifty-six patients died in this study. On average, they experienced a 50% decline in 
SAL prior to death. Patients (n=129) who dropped their SAL below threshold were more 
likely to be older, male, diabetic and have more symptomatic heart failure. They also had a 
significantly increased risk of heart failure/death (HR 3.6, 95% CI 2.3-5.8, p<0.0001) or 
death (HR 4.2, 95% CI 2.2-7.7, p<0.0001) compared to those who had sustained activity 
levels. Lower baseline activity level was also associated with significantly increased risk of 
heart failure/death and death.  
Conclusion: Significant decline in device-derived activity level and low baseline activity 
level are associated with increased mortality and heart failure in patients with an ICD for 










Implantable defibrillators and pacemakers continuously collect a variety of prognostically 
validated patient parameters, including activity level.  Each device company uses their own 
unique proprietary algorithms to calculate and report these values (1). The available graphical 
data is not easily interchangeable and comparable across different companies and different 
time points in a patient’s care especially in clinical practice (Supplemental Figure A). 
Previous studies demonstrating the prognostic importance of device-derived activity typically 
included patients enrolled in clinical studies with devices from one major company only (2-
7). Given the company-specific proprietary algorithms, limited real-world data, and 
limitations in cross-company comparisons, device-derived activity level has not been readily 
integrated in clinical practice (1). Such data, in combination with other parameters, has the 
potential to identify clinical decompensation before the onset of symptoms but requires 
further validation in a real-world cohort using devices from several manufacturers.   
The purpose of this study is to address this deficit by assessing the prognostic significance of 
device-derived activity level, across multiple companies, in a high volume outpatient clinical 
practice. We designed this descriptive retrospective study to assess the prognostic value of 
baseline activity level and change in activity in predicting heart failure and all-cause 
mortality.   
METHODS:  
 
Study Population:  
This was a single center, retrospective study which included all patients who underwent 
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May of 2014 to December of 2016. Patients were excluded if they died within 5 weeks of 
implantation or did not have post-implantation data available.  The defibrillators implanted 
included those capable of biventricular pacing and were produced by Medtronic 
(Minneapolis, Minnesota, USA), Boston-Scientific (Marlborough, Massachusetts, USA), 
Biotronik (Berlin, Germany) and St. Jude (Memphis, Tennessee, USA).  The study protocol 
was approved the Institutional Review Board at the University of Michigan prior to initiation 
of the study.  
Collection of Patient Activity Level:  
All implanted devices in this study were capable of storing continuous patient activity level 
based on company proprietary algorithms. The data was presented graphically and stored for 
varying duration at the time of periodic device interrogations in-clinic and via home-
monitoring, if applicable.  Post-mortem device interrogations were not performed at our 
institution. Continuous graphical data for patient activity was retrospectively collected from 
stored device interrogations and processed anonymously. Graphical data was converted to 
numerical values using non-commercially available, open source software (Engauge 
Digitizer, version 10.8).  This data was then used for further analysis.  
Baseline Activity, Standardization and Grouping:  
The average activity level over a month following a week post-implantation was used as the 
baseline value in our study. The duration and timing for this baseline value is based on our 
clinical experience managing patients post-implantation and to maximize the observational 
window. Subsequent weekly average activity levels (SAL) up to two years post-implantation 
were then standardized to this baseline to allow comparison among devices over time 
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explantation, upgrade or change. Baseline activity level was also used to stratify and group 
patients based on median activity level by device company (Supplemental Table 2). Those in 
each median of activity were then combined across all companies for further stratification.  
Optimal Threshold of Standardized Activity Level:  
The primary predictor variable was a weekly SAL below 59.4% within two years following 
device implantation. This threshold was used to define declining physical activity as it was 
previously reported (4) to be associated with increased risk of adverse cardiovascular 
outcomes including death.  
Outcomes of interest:  
The outcomes of interest for this study were the combination of heart failure hospitalization 
and death and all-cause mortality. The date and etiology of death was obtained from the 
individual review of the electronic medical record.  Heart Failure events were defined as a 
hospital admission requiring intravenous diuresis. These events identified for each patient in 
our cohort using DataDirect, an electronic medical search application offered through the 
University of Michigan Office Research. Patients admitted with a primary admission 
diagnosis of heart failure were first identified using standard International Classification of 
Diseases codes for acute and acute on chronic heart failure (ICD 9 and 10 codes: 428.* and 
I50.*). Charts were then reviewed to ensure accuracy of diagnostic coding. Over seventy-five 
percent of coded admissions were done so accurately and were included in the study. 
Statistical Analysis:  
Baseline characteristics were compared using the Chi square test or t-test as indicated. 
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analysis with SAL as a time-dependent variable. Cox models were adjusted for age, gender, 
left ventricular ejection fraction, biventricular pacing, and severity of heart failure (NYHA 
Class III-IV); these variables were selected a priori based on their clinical relevance to the 
outcome of interest (8-10).  The proportional hazards assumption was fulfilled for the model 
incorporating heart failure/death but not all-cause mortality itself. Kaplan-Meier and 
multivariable cox proportional analysis (static variables) were also used to demonstrate 
cumulative incidence of our end-points based on baseline activity level. GraphPad Prism 8 
(Prism, San Diego, California) and Stata 15 (StataCorp, College Station, Texas) were used 
for analyses. 
 
RESULTS:   
 
Demographics: 
Two hundred and eighty-nine patients underwent device placement over the study period. 
Three were excluded due to death shortly after implant, and 6 were lost to follow up after five 
weeks for a final population of 280 patients. Implanted devices included models from Boston 
Scientific (n=122), Medtronic (n=109), and St.Jude/Biotronik (n=49). There were no major 
adverse events directly attributable to device implantation. 
Of the 280 patients enrolled in this study, 129 had at least one week of significantly reduced 
SAL following standardization within two years of implantation. Patients who met threshold 
reduction in weekly SAL were more likely to be older, male, diabetic with NYHA class III-
IV symptoms (Table 1). Patients after meeting SAL threshold had a median follow up period 
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Cause of Death and Standardized Activity Level Prior to Death:  
Fifty-six patients died in the follow up period. The majority of patients who died of an 
identifiable cause (n=42) died of a cardiac process (end stage heart failure n=15, cardiogenic 
shock n=6, sudden cardiac death n=6, Supplemental Table 1). Patients who died had on 
average lower SAL compared to those who did not and experienced a significant progressive 
reduction in their SAL weeks prior to death (Supplemental Figure C).   
Prognostic Significance of Threshold SAL as a Time-Dependent Variable: 
Using Cox Proportional-Hazards Regression with SAL as a time-dependent variable, patients 
whose weekly SAL declined below threshold of 59.4% had a higher incidence of death and 
heart failure/death compared to those who did not (Figure 1A-B). Adjusted cox proportional 
hazard modeling with SAL as a time-dependent variable demonstrated that meeting SAL 
threshold was associated with a significantly increased risk of heart failure/death (HR 3.6, 
95% CI 2.3-5.8, p<0.0001) and death (HR 4.2, 95% CI 2.2-7.7, p<0.0001). 
Prognostic Significance of Baseline Activity Level: 
To assess the prognostic significance of baseline activity, patients were stratified by median 
baseline activity level in each company and combined.  Using Kaplan-Meier survival 
analysis, those in the lower half of baseline activity had a significantly increased three-year 
cumulative incidence of heart failure/death (38.3% vs. 17.4%, log rank p<0.0001) and death 
(25.8% vs. 9.4%, log rank p<0.0001) compared to those with the higher baseline activity 
(Figure 2). 
After adjusting for relevant clinical covariates, patients with higher baseline activity were at a 
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Those in the upper half had a 51% (95% CI 0.22-0.70, p<0.0001) reduced risk of heart 
failure/death and 58% (95% CI 0.19-0.78, p<0.0001) reduced risk of death compared to those 
with lower baseline activity (Table 2). 
Prognostic Significance of Baseline Activity Level and Threshold SAL:   
Among patients who dropped their weekly activity level past identified threshold (SAL 
<59.4%), baseline activity provided significant risk differentiation per Kaplan-Meier survival 
analysis. In this patient population, those in the lower half of baseline activity level had a 
significantly increased three-year cumulative incidence of heart failure/death (67.3% vs. 
33.7%, log rank p<0.0001) and death (49.3% vs. 15.3%, log rank p<0.0001) compared to 
those with higher baseline activity level (Figure 3A).  
In patients who did not drop their activity level, baseline activity was not a significant 
differentiator. Although patients in the lower half of baseline activity with consistent SAL 
had higher three-year cumulative incidence of heart failure/death (21.8%, 11.4%, p=0.08) and 









We have demonstrated in this study that baseline and change in device-derived activity level 
is a prognostic predictor of death/heart failure and death in patients with a defibrillator for 
primary prevention across multiple device companies. Patients who experience a near 41% 
reduction in their activity level for at least one week fare poorly compared to those who do 
not. Likewise, those with reduced baseline activity level post-implantation are at an increased 
risk of dying and experiencing a heart failure event compared to those with higher baseline 
activity level.  The majority of events occur shortly after the decline. Per our data, the highest 
risk patients are those with reduced baseline activity who subsequently experience a drop in 
their activity level. These patients have significantly elevated 3-year cumulative incidence of 
death (49%) and heart failure/death (67%).  Taken together, this suggests that device-derived 
activity level can help risk stratify patients soon after device implantation.  
Activity data is continuously collected by a range of different implantable devices – from 
pacemakers, defibrillators and even loop recorders – in a variety of different patients. These 
device-derived activity levels have been previously shown to correlate with validated 
hemodynamic testing including six-minute walk test and external accelerometers (11-17). 
Others, using single-device registries or studies (Medtronic and Boston Scientific), have also 
shown the prognostic significance of device-derived activity.  
A retrospective study by Conraads et al enrolled 836 patients with a Medtronic ICD or CRT-
D device. The authors demonstrated that the initial 30-day average device-derived activity 
corresponded with death or heart failure hospitalization (3). Subsequently Kramer et al, in a 
retrospective study of Boston Scientific LATITUDE database, showcased the significance of 
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also fared poorly in their analysis (5). Finally, Jamé et al in a retrospective study of MADIT-
CRT data, demonstrated the prognostic value of a decline in device-derived activity level in 
patients with Boston-Scientific Devices.  Patients whose activity level declined by forty 
percent, which was a threshold used in this study as well, had increased adverse 
cardiovascular events (4). This study further advances the above findings. We have shown 
that a significant decline from baseline activity level in patients with devices from multiple 
companies is of a strong clinical value and is applicable to a large outpatient clinical practice.  
Although ubiquitous and, as shown, objectively relevant, the clinical integration of device-
derived activity is difficult. There are significant obstacles arising from data representation at 
the time of interrogation and the absence of an available baseline for any comparison. 
Depending on the device company, the graphically reported data is shown for varying 
durations with no comparison to a baseline or prior interrogation. Due to the proprietary 
nature of the algorithms used to calculate and process activity level and the absence of 
publicly available data, the absolute reported values are not comparable across different 
companies or to other patients (1). As a result, current utility of device-derived activity level 
is limited.  We hope to raise awareness of the clinical utility of this often clinically neglected 
value and highlight the need for better reporting and clinical integration.   
Additionally, the median absolute baseline activity-level value for each company can be 
found in our supplemental figures (Supplemental Table 2). We hope that by reporting these 
values, other researchers can validate our findings in their respective patient cohorts and, 
more importantly, providers can begin to incorporate activity level in stratifying their patients 
immediately post-implantation across multiple companies.  We have shown in this study that 
patients with lower activity level do poorly independently of age, heart failure severity and 
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Likewise, we are hopeful that the nearly 40% decline threshold used in this study can serve as 
an easily identifiable cut-off for other providers in risk stratifying patients. The underlying 
etiology of activity decline in our patients appears to be nonspecific and ranges from both 
cardiovascular (heart failure progression, worsening valvular function, or arrhythmias) to 
non-cardiovascular events (falls, strokes, surgeries, or infections).  In our cohort, patients 
whose activity level remained stable fared well compared to those whose activity level met 
this threshold. Regardless of the underlying etiology, it appears that a significant decline in 
objective activity level requires further evaluation and serves as a useful clinical vital sign.  
Further validation of our findings is necessary. It also remains to be seen if clinical 
intervention in those with declining activity level has any impact on outcomes. At the very 
least, device-derived activity level can help serve as an additional objective parameter in the 
overall clinical assessment of patients and potentially help patients and providers in their 
preparation for end of life care.  
Limitations: 
There are specific limitations associated with this study given its retrospective nature. 
Continuous activity levels could not be ascertained post-implantation for all patients due to 
deficiencies in patient follow up. Likewise, St. Jude and Biotronik devices do not record 
activity level during episodes of atrial arrhythmias by the nature of their proprietary 
algorithms. Furthermore, our SAL cut-off threshold of 59.4% (sensitivity 70.1%; specificity 
79.5%) was validated in a similar patient population but only included patients undergoing 
biventricular pacing. 
Additionally, the outcomes assessed in this study were obtained through chart review. Heart 
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included in this study. Although the electronic medical system allowed for across-
institutional identification of mortality, the underlying etiology was not readily available. 
Finally, post-mortem interrogations were not performed at our institution.  
Conclusion:  
In patients with a defibrillator for primary prevention, low baseline and a decline in device-
derived activity level help identify patients at increased risk of dying.   
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Table 1: Baseline demographics of the total cohort and the subsequent two randomized 
subgroup populations. 
Clinical Characteristics SAL≤ 59.4% SAL > 59.4% P Value 
Number of Patients 
129 151  
Boston 53 68  
Medtronic 55 55  
Biot/St. Jude 21 28  
Male (%) 90 (69.7) 91 (60.2) 0.03 
Age 64.3 59.9 0.006 
CRT (%) 67 (51.9) 65 (43.0) 0.30 
Non-ischemic 69 (53.4) 73 (48.3) 0.28 
LVEF 28.2 30.8 0.39 
NYHA III-IV 75 (58.1) 58 (38.4) 0.02 
Diabetes 50 (38.8) 41 (27.2) 0.04 
Diagnosis of HF 118 (91.4) 127(84.1) 0.56 
QRS 131.2 122.9 0.30 
BUN 27.1 22.8 0.24 
Abbreviations: CRT– Cardiac Resynchronization, LVEF – Left Ventricular Ejection 
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Table 2:  Multivariate Analysis of death and heart failure/death comparing upper to lower 
half baseline activity level.  HR, hazard ratio; 95% CI, 95% confidence interval;  
Table 2 
Upper vs. Lower Half Baseline Activity Level 
HR 95% CI p-value 
Death 0.42     0.22 – 0.81 <0.0001 
Heart Failure/Death 0.49    0.31- 0.79 <0.0001 
 
Model was adjusted for the following covariates: Age, Gender, Systolic Function (LVEF), Severity of 




















Figure 1A-B: Graphical survival curve estimates for heart failure/death (1A) and death (1B) from SAL 









Figure 2: Three-year cumulative incidence of the death and heart failure/death from standardization 










Figure 3A-B: Three-year cumulative incidence of death and heart failure/death based on SAL 
(reduced-3A and sustained-3B) and baseline activity level half (lower half or upper half) 
 
 
